TLR7 AGONIST AND COMBINATIONS FOR CANCER TREATMENT

The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ROSEMANN, ROMAN, STROBL, STEFAN, SAHIN, UGUR, HASSAN, HARIZ ISKANDAR BIN
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer. La présente invention concerne l'agoniste de TLR7 spécifique BNT411, ainsi que des compositions et des kits comprenant BNT411, et l'utilisation de BNT411 en tant qu'agent immunothérapeutique en monothérapie et polythérapie pour réduire ou prévenir la progression d'une tumeur, en particulier d'une tumeur solide, ou traiter le cancer, en particulier un cancer solide.